Synapse Open Synapse
Biology

Biopharma likely to climb higher after ‘blue wave,’ analysts say

BioPharma Dive · · 3 min read

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.

Latest from BioPharma Dive